Investor Presentaiton

DNA Operating free cash flow at a good level Cash flow summary EUR million 2015 2016 2017 2018 2018* Key highlights in 2018 Operating free cash flow at a good level + EBITDA significantly higher year-on-year +Operating FCF increased 7.3% from the reference year Free cash flow to equity EUR 72 million (end of September 2018: EUR 57 million) The higher costs resulting from the re-financing of bonds in the first quarter weakened cash flow Net working capital related to trade payables increased due to the payment of previous year's high investments. Also increase in sales receivables due to high equipment sales impacted NWC negatively. - Investments distributed more evenly this year Comparable EBITDA 227 247 272 284 285 Operative Capex (148) (137) (133) (135) (134) Operating FCF 79 110 139 149 151 Margin % 9.5% 12.8% 15.7% 16.3% 16.6% Cash Conversion % 34.7% 44.6% 51.1% 52.5% 53.0% Interest paid, net (8) (9) (9) (17) (17) - Income taxes, paid 2 (5) (26) (12) (12) Adjusted Change in NWC 38 (1) 19 (46) (48) Change in Provisions (9) (2) (5) (2) (2) FCFE 101 93 119 72 72 Margin % 12.2% 10.8% 13.4% 7.9% 7.9% Notes *Including IFRS 15 DNA's Investor presentation, February 2019 29 29

View entire presentation